Disease, Disability, and Injury Prevention and Control Special Emphasis Panels: Prevention of the Complications of Bleeding Disorders Through Hemophilia Treatment Centers, Request for Applications (RFA) DD06-005, 34373-34374 [E6-9269]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 114 / Wednesday, June 14, 2006 / Notices
• Public and private programs should
support training for health professionals
to emphasize proactive, individualized
care planning and clear communication
between providers, patients and their
families.
• At the community level, funding
should be made available for support
services to assist individuals and
families in accessing the kind of care
they want for last days.
Members of the Citizens’ Health Care
Working Group
Randall L. Johnson, Chair
Frank J. Baumeister, Jr.
Dorothy A. Bazos
Montye S. Conlan
Richard G. Frank
Joseph T. Hansen
Therese A. Hughes
Brent C. James
Catherine G. McLaughlin
Patricia A. Maryland
Rosario Perez
Aaron Shirley
Deborah R. Stehr
Christine L. Wright
Michael O. Leavitt, Secretary of Health
and Human Services
Because the Working Group’s final
recommendations will be submitted to
the Department of Health and Human
services, the Secretary of Health and
Human Services has neither
participated in the development of these
recommendations nor has he endorsed
them. He will carefully consider them
and take appropriate action.
End of Review Text
Additional materials including a
description of how the Working Group
did its work, key findings from the
dialogue with the American people,
stories from Americans, and background
material on the demographics and
health resources of locations where
Working Group community meetings
were held, findings from the Working
Group’s internet poll and University
town hall meeting, and a summary of
presentations made to the Working
Group can be found on the Working
Group’s Web site:
www.citizenshealthcare.gov.
rwilkins on PROD1PC63 with NOTICES
Authority: This notice is published in
accordance with section 10(a) of the Federal
Advisory Committee Act.
The Medicare Modernization Act
charged AHRQ with administering the
funds provided by the Congress for the
activities of the Citizens’ Health Care
Working Group. However, AHRQ has
not participated in the development of
these recommendations or supporting
material, has had not advance
knowledge of their content, and
publication of this notice is not an
VerDate Aug<31>2005
19:47 Jun 13, 2006
Jkt 208001
endorsement of the Working Group’s
recommendations by AHRQ or the
Department of Health and Human
Services.
Carolyn M. Clancy,
Director.
[FR Doc. 06–5379 Filed 6–13–06; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Notice of Meeting
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AHRQ), and agree to be available, to
conduct on an as needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications submitted in response to
the Request for Applications (RFA)
Number: RFA–HS–06–030, Improving
Patient Safety through Simulation
Research, are to be reviewed and
discussed at this meeting. These
discussions are likely to reveal personal
information concerning individuals
associated with the applications. This
information is exempt from mandatory
disclosure under the above-cited
statutes.
SEP Meeting on: Improving Patient
Safety through Simulation Research,
July 11–13, 2006.
Date: July 11, 2006 (Open on July 11
from 7 p.m. to 7:15 p.m. and closed for
the remainder of the meeting).
Place: Marriott Gaithersburg
Washingtonian, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Date: July 12–13, 2006 (Closed
meeting).
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
34373
Place: John M. Eisenberg Building,
540 Gaither Road, Suite 2020, Rockville,
Maryland 20850.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the non-confidential portions
of this meeting should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Room 2038, Rockville,
Maryland 20850, telephone (301) 427–
1554.
Agenda items for this meeting are
subject to change as priorities dictate.
Dated: June 2, 2006.
Carolyn M. Clancy,
Director.
[FR Doc. 06–5378 Filed 6–13–06; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panels: Prevention of the
Complications of Bleeding Disorders
Through Hemophilia Treatment
Centers, Request for Applications
(RFA) DD06–005
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel: Prevention of the Complications of
Bleeding Disorders through Hemophilia
Treatment Centers, RFA DD06–005.
Time and Date: 8 a.m.–5 p.m., June 28,
2006 (Closed).
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Building
19, Room 256/257, Atlanta, GA 30333.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: To conduct
expert review of scientific merit of research
applications in response to RFA DD06–005,
‘‘Prevention of the Complications of Bleeding
Disorders through Hemophilia Treatment
Centers.’’
For Further Information Contact:
Juliana Cyril, Ph.D., Scientific Review
Administrator, Centers for Disease
Control and Prevention, 1600 Clifton
Road, NE., Mailstop D72, Atlanta, GA
30333, Telephone 404.639.4639.
E:\FR\FM\14JNN1.SGM
14JNN1
34374
Federal Register / Vol. 71, No. 114 / Wednesday, June 14, 2006 / Notices
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: June 8, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–9269 Filed 6–13–06; 8:45 am]
BILLING CODE 4163–18–P
and Prevention, 1600 Clifton Road NE.,
MS E–07, Atlanta, GA 30333, Telephone
404.639.8531.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: June 8, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–9270 Filed 6–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: HIV Prevention
Projects for Young Men of Color Who
Have Sex With Men and Young
Transgender Persons of Color,
Funding Opportunity Announcement
(FOA) PS06–618
Centers for Disease Control and
Prevention
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
rwilkins on PROD1PC63 with NOTICES
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel: HIV Prevention Projects for Young
Men of Color Who Have Sex With Men and
Young Transgender Persons of Color, FOA
PS06–618.
Times and Dates:
9 a.m.–12 p.m., June 26, 2006 (Closed).
9 a.m.–5 p.m., June 27, 2006 (Closed).
9 a.m.–5 p.m., June 28, 2006 (Closed).
9 a.m.–5 p.m., June 29, 2006 (Closed).
9 a.m.–5 p.m., June 30, 2006 (Closed).
Place: W Hotel Atlanta at Perimeter Center,
111 Perimeter Center West, Atlanta, Georgia
30346, Telephone 770.396.6800.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to ‘‘HIV Prevention Projects for
Young Men of Color Who Have Sex With
Men and Young Transgender Persons of
Color,’’ FOA PS06–618.
For Further Information Contact: Beth
Wolfe, Resource Funding Analyst,
Funding Activities Services Office,
Extramural Funding Activities Unit,
National Center for HIV, STD, and TB
Prevention, Centers for Disease Control
VerDate Aug<31>2005
19:47 Jun 13, 2006
Jkt 208001
Request Form’’ and register online at
https://www.cdc.gov/nip/acip. The access
request form can be obtained by contacting
Demetria Gardner at 1–404–639–8836 and
should be e-mailed upon completion directly
to Ms. Gardner at dgardner@cdc.gov.
For Further Information Contact: Demetria
Gardner, Immunization Services Division,
National Center for Immunization and
Respiratory Diseases (proposed), CDC, 1600
Clifton Road, NE., (E–05), Atlanta, Georgia
30333, telephone 404/639–8836, fax 404/
639–8905.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: June 8, 2006.
B. Kathy Skipper,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E6–9266 Filed 6–13–06; 8:45 am]
BILLING CODE 4163–18–P
Advisory Committee on Immunization
Practices: Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following Federal
Committee meeting.
Correction: This notice was published
in the Federal Register on June 9, 2006,
volume 71, number 111, pages 33456–
33457. ‘‘Additional Information’’ that
was published on April 3, 2006, volume
71, number 63, page 16582, and a
change to the ‘status’ has been added.
Name: Advisory Committee on
Immunization Practices (ACIP).
Times and Dates:
8 a.m.–6 p.m., June 29, 2006.
8 a.m.–4 p.m., June 30, 2006.
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Building
19 (Global Communications Center), Room
232, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available. Meeting space
accommodates approximately 330 people.
Overflow space for real-time viewing will be
available.
Additional Information: In order to
expedite the security clearance process at the
CDC Clifton Road Campus, all ACIP
attendees are now required to register online
at https://www.cdc.gov/nip/acip, which can
be found under the ‘‘Upcoming Meetings’’
tab. Please be sure to complete all the
required fields before submitting your
registration and submit no later than June 22,
2006.
Please Note: All non-U.S. Citizens must
pre-register by June 18, 2006 or they will not
be allowed access to the campus and will not
be allowed to register on site. All non-U.S.
Citizens are required to complete the ‘‘Access
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2002E–0100]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; DUTASTERIDE
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
DUTASTERIDE and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of Patents and Trademarks,
Department of Commerce, for the
extension of a patent that claims that
human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy (HFD–7), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–594–2041.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
E:\FR\FM\14JNN1.SGM
14JNN1
]]>Agencies
[Federal Register Volume 71, Number 114 (Wednesday, June 14, 2006)]
[Notices]
[Pages 34373-34374]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9269]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panels: Prevention of the Complications of Bleeding Disorders
Through Hemophilia Treatment Centers, Request for Applications (RFA)
DD06-005
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting:
Name: Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel: Prevention of the Complications of Bleeding
Disorders through Hemophilia Treatment Centers, RFA DD06-005.
Time and Date: 8 a.m.-5 p.m., June 28, 2006 (Closed).
Place: Centers for Disease Control and Prevention, 1600 Clifton
Road, NE., Building 19, Room 256/257, Atlanta, GA 30333.
Status: The meeting will be closed to the public in accordance
with provisions set forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: To conduct expert review of scientific
merit of research applications in response to RFA DD06-005,
``Prevention of the Complications of Bleeding Disorders through
Hemophilia Treatment Centers.''
For Further Information Contact:
Juliana Cyril, Ph.D., Scientific Review Administrator, Centers for
Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop D72,
Atlanta, GA 30333, Telephone 404.639.4639.
[[Page 34374]]
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: June 8, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-9269 Filed 6-13-06; 8:45 am]
BILLING CODE 4163-18-P
